anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses an enzymolysis method of ovalbumin, comprising the following steps: (1) ovalbumin, papaya peplidase, L-cysteine and distilled water are uniformly mixed to carry out an enzymolysis reaction, wherein amino acid sequence of papaya peplidase is sequence as shown in SEQ ID NO:1; (2) a mixture obtained after enzymolysis in the step (1) is heated, and ovalbumin residue which hasn't undergone enzymolysis is filtered and removed; and (3) enzymolysis products obtained after processing in the step (2) are sterilized. Simple, low-cost and high-purity extraction of papaya peplidase from papaya latex is realized. In addition, papaya peplidase is a natural biologically-active substance. By the use of the peptidase for enzymolysis of ovalbumin, low-molecular oligopeptides and amino acid with molecular weight being 500-1000 can be obtained. The enzymolysis rate is high. The low-molecular oligopeptides and amino acid can be used as medicines for treating hepatopathy and also can further promote absorption of organisms and skin.
Cleft palate repair is a common reconstructive procedure that can involve significant blood loss. Tranexamic acid (TXA) has been proposed to minimise blood loss during various surgical procedures, but its effectiveness in cleft palate repair remains unclear. This systematic review and meta-analysis aimed to assess the effectiveness of TXA to reduce postoperative blood loss. Adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, we conducted a comprehensive search across multiple databases, including PubMed, Cochrane, and Web of Science, to identify relevant studies published up to September 2023. Only randomised controlled trials (RCTs) were included. Primary outcomes measured were total blood loss, transfusion rates, and postoperative complications. We identified four relevant RCTs, which included 275 cleft palate patients with a mean (range) age of 28.7 (6-65) months. The pooled analysis found no significant difference in duration of surgery (MD -18.40 minutes, p = 0.09), preoperative haemoglobin (MD 0.46 g/dl, p = 0.27), or postoperative haemoglobin (MD 0.07 g/dl, p = 0.86) between TXA and control groups. Intraoperative blood loss was lower with TXA, but with TXA, the difference was not statistically significant (MD -16.63 ml, p = 0.15). TXA significantly improved surgical field visibility (p = 0.004). No adverse events occurred with its use. While no significant differences were found in surgical outcomes with TXA, surgical field visibility significantly improved, and TXA showed a promising safety profile. Larger and higher-quality RCTs are still needed to validate these preliminary findings before TXA can be considered as a standard treatment.
OBJECTIVE: To provide a quantitative comparison between myocardial revascularization (REVASC) and optimal medical treatment (OMT) alone in patients with chronic coronary syndrome (CCS).
METHODS: Pertinent studies were searched for in PubMed/Medline until 12/03/2023. Randomized controlled trials that compare REVASC to OMT reporting clinical outcomes were selected according to PRISMA guidelines. The primary outcome was cardiovascular death. Two investigators independently assessed the study quality and extracted data.
RESULTS: Twenty-eight randomized controlled studies (RCTs) including 20692 patients were included in this meta-analysis. The rate of cardiovascular mortality was significantly lower among patients treated with myocardial revascularization [risk ratio (RR) 0.79, 95% CI 0.69-0.90]. Age (p = 0.03), multivessel disease (p < 0.001), and follow-up duration (p = 0.001) were significant moderators of CV mortality. Subgroup analyses showed a larger benefit in patients treated with drug-eluting stents and those without chronic total occlusion. Among secondary outcomes, myocardial infarction was less frequent in the REVASC group (RR = 0.74; p < 0.001), while no significant difference was found for all-cause mortality (p = 0.09) nor stroke (p = 0.26).
CONCLUSIONS: The present analysis showed lower rates of CV mortality and myocardial infarction in CCS patients treated with myocardial revascularization compared to OMT. This benefit was larger with increasing follow-up duration. Personalized treatment based on patient characteristics and lesion complexity may optimize clinical outcomes in patients with CCS.
The invention discloses a shampoo for preventing hair loss and growing hair and a preparation method thereof. The shampoo comprises active ingredients, wherein the active ingredients comprise a salvia miltiorrhiza extract, an angelica sinensis extract, a safflower extract, an astragalus membranaceus extract, a polygonum multiflorum extract and camellia seed polypeptide. The active ingredients consisting of the salvia miltiorrhiza extract, the angelica sinensis extract, the safflower extract, the astragalus extract, the polygonum multiflorum extract and the camellia seed polypeptide can improve the activity of hair papilla cells treated by dihydrotestosterone. In vitro experiments show that secretory factors IGF-1, VEGF, DKK-1, TGF beta 2, IL-6 and the like of the hair papilla cells and beta-catenin and AR all return to normal levels. The shampoo is used for patients with alopecia and sparse hair every 3 days. The effective rate of the alopecia patient is 85%, and the effective rate of the hair thinning patient is 98%.
BACKGROUND: The management of type 2 diabetes (T2D) and obesity, particularly in the context of self-monitoring, remains a critical challenge in health care. As nearly 80% to 90% of patients with T2D have overweight or obesity, there is a compelling need for interventions that can effectively manage both conditions simultaneously. One of the goals in managing chronic conditions is to increase awareness and generate behavioral change to improve outcomes in diabetes and related comorbidities, such as overweight or obesity. There is a lack of real-life evidence to test the impact of self-monitoring of weight on glycemic outcomes and its underlying mechanisms.
OBJECTIVE: This study aims to assess the efficacy of digital self-monitoring of weight on blood glucose (BG) levels during diabetes management, investigating whether the weight changes may drive glucose fluctuations.
METHODS: In this retrospective, real-world quasi-randomized study, 50% of the individuals who regularly used the weight monitoring (WM) feature were propensity score matched with 50% of the users who did not use the weight monitoring feature (NWM) based on demographic and clinical characteristics. All the patients were diagnosed with T2D and tracked their BG levels. We analyzed monthly aggregated data 6 months before and after starting their weight monitoring. A piecewise mixed model was used for analyzing the time trajectories of BG and weight as well as exploring the disaggregation effect of between- and within-patient lagged effects of weight on BG.
RESULTS: The WM group exhibited a significant reduction in BG levels post intervention (P<.001), whereas the nonmonitoring group showed no significant changes (P=.59), and both groups showed no differences in BG pattern before the intervention (P=.59). Furthermore, the WM group achieved a meaningful decrease in BMI (P<.001). Finally, both within-patient (P<.001) and between-patient (P=.008) weight variability was positively associated with BG levels. However, 1-month lagged back BMI was not associated with BG levels (P=.36).
CONCLUSIONS: This study highlights the substantial benefits of self-monitoring of weight in managing BG levels in patients with diabetes, facilitated by a digital health platform, and advocates for the integration of digital self-monitoring tools in chronic disease management. We also provide initial evidence of testing the underlying mechanisms associated with BG management, underscoring the potential role of patient empowerment.
Non-invasive imaging evaluation of GRPR expression would be of great help in drug development, patient stratification and therapeutic response monitoring. Various GRPR targeting imaging probes have been develop to meet the purpose. Bombesin (BBN) is an amphibian homolog of mammalian gastrin-releasing peptide (GRP). BBN(7-14), with the amino acid sequence of Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH2, has been extensively used for the development of molecular probes for the imaging of gastrin-releasing peptide receptor (GRPR), after being labeled with various radionuclides. Multiple preclinical studies have demonstrated receptor-specific accumulation of the tracers in GRPR positive tumors. For interests in clinical translation of 68Ga-NOTA-Aca-BBN(7-14), an open-label dynamic whole-body PET/ CT study was designed to investigate the safety and diagnostic performance of 68Ga-NOTA-Aca-BBN(7-14) in patients with glioma.
A system (10) for enabling medical consultation online is disclosed. The system includes a processing subsystem (20) which includes a registration module (50). The processing subsystem includes a specialist search module (80) to search for a first health care professional by a second health care professional. The processing subsystem includes an appointment management module (90) to reserve an appointment of the first health care professional. The processing subsystem includes a consultation module (100) to avail a consultation of first health care professional by the second health care professional. The consultation module is to provide medical records of patients relevant to the consultation. The processing subsystem includes a diagnostic module (110) to prepare a transcript of the consultation. The diagnostic module is to identify medical conditions of the patients. The diagnostic module is to recommend additional medical procedures to the patients.
Participants in this group will be treated with two infusions of vehicle along with heparin (blood thinner) in addition to standard of care treatment. The first infusion will be administered within 24 hours of study enrollment and the second infusion will be administered within 72 hours of study enrollment.
Bioavailable compositions are provided. The bioavailable compositions comprise emulsions. The emulsions comprise: water; a cannabinoid; a carrier; an emulsifier; and a THC antagonist. The bioavailable compositions may further comprise a cyclodextrin, an excipient, and a terpene. The bioavailable compositions may comprise thin films. The thin films may be mucosally dissolvable films.
PROBLEM TO BE SOLVED: To obtain a soft capsule film excellent in solubility, adhesion resistance and appearance, without mutual adhesion and adhesion to a storage vessel and capable of obtaining soft capsule formulations having good appearance by adding silk. SOLUTION: A soft capsule film is obtained by adding silk. This soft capsule film is preferably obtained by adding silk to a film base material such as gelatin. The silk is a type of amino acids having 90 average molecular weight and >=5 wt.%, preferably 2 wt.% of silk of the amino acid type is added to the gelatin. The silk is preferably a peptide type having 500 average molecular weight and a protein type having 1-5 μm average size. The amino acid type adopted as the silk is obtained by thoroughly hydrolyzing silk fiber, the peptide type is obtained by hydrolyzing silk fiber to a certain degree and the protein type is obtained by mechanically pulverizing silk fiber.
Invasive lobular carcinoma (ILC) is known to account for about 10-15% of all invasive breast cancer and is the second most common subtype of breast cancer following invasive ductal carcinoma (IDC). ILC is histologically characterized by the loss of E-cadherin involved in cell adhesion, which contributes to the growth and infiltration of tumors in the characteristic non-adhesive single cell layer pattern of ILC\]. Therefore, ILC often has no tumors detected by physical examinations and the sensitivity of mammography being reported to be 34%, which is much lower than IDC (81%). Therefore, the diagnosis of ILC is often delayed, the tumor size is larger and the stage is higher than that of IDC at the first visit. The diagnostic accuracy of breast ultrasound for axillary lymph node metastasis is reported as 55-92% for sensitivity and 80-97% for specificity. However, in the case of ILC, the diagnostic performance is significantly lower than this. According to the previous study on ILC, mammography had 7% of sensitivity, ultrasound had 26%, and MRI had 7% in diagnosing axillary lymph node metastasis with 38% of patients having false positive results for axillary lymph node metastasis. This is related to ILC-specific metastasis patterns in which only cells are replaced by cancer cells while maintaining the normal structure of the lymph node and the absence of desmoplastic reaction. The NCCN guideline recommends that during axillary lymph node resection, resection is performed up to level III if lymph node metastasis is confirmed or suspected in axillary level II or III. Preoperative chemotherapy should be considered for lymph node metastasis of cN3 or Bulky or matted cN2 stage. Considering the limited diagnostic accuracy of those standard imaging tests for diagnosis of axillary lymph node metastasis, \[18F\]FES PET/CT may help change treatment strategy, such as changing the extent of axillary lymph node resection or performing neoadjuvant chemotherapy instead of upfront surgery in patients with ILC. In addition, considering that high rate of distant metastasis and limited diagnostic accuracy of preexisting imaging modality in ILC, \[18F\]FES PET/CT is likely to help treatment decision making by discovering unexpected distant metastases. It is reported that the implementation of \[18F\]FES PET/CT contributed to the change in treatment policy in about 26% of patients compared to conventional standard imaging and \[18F\]FDG PET/CT. Currently in South Korea, reimbursement of \[18F\]FES PET/CT is limited to patients with recurrent or metastatic breast cancer whose lesions are located in the cervical spine, upper thoracic, pelvic, peritoneum, pleural, and mediastinal lymph nodes.
Rotavirus (RV) infection is a major cause of acute gastroenteritis in children under 5 years old, resulting in elevated mortality rates in low-income countries. The efficacy of anti-RV vaccines is limited in underdeveloped countries, emphasizing the need for novel strategies to boost immunity and alleviate RV-induced diarrhea. This study explores the effectiveness of interventions involving extracellular vesicles (EVs) from probiotic and commensal E. coli in mitigating diarrhea and enhancing immunity in a preclinical model of RV infection in suckling rats. On days 8 and 16 of life, variables related to humoral and cellular immunity and intestinal function/architecture were assessed. Both interventions enhanced humoral (serum immunoglobulins) and cellular (splenic natural killer (NK), cytotoxic T (Tc) and positive T-cell receptor γδ (TCRγδ) cells) immunity against viral infections and downregulated the intestinal serotonin receptor-3 (HTR3). However, certain effects were strain-specific. EcoR12 EVs activated intestinal CD68, TLR2 and IL-12 expression, whereas EcN EVs improved intestinal maturation, barrier properties (goblet cell numbers/mucin 2 expression) and absorptive function (villus length). In conclusion, interventions involving probiotic/microbiota EVs may serve as a safe postbiotic strategy to improve clinical symptoms and immune responses during RV infection in the neonatal period. Furthermore, they could be used as adjuvants to enhance the immunogenicity and efficacy of anti-RV vaccines.
This is a Phase 1, randomized, placebo-controlled, multicenter study of CNTO 7160. The study consists of Screening Period, In-patient period (6 days for healthy participants, 11 days for asthmatic participants and atopic dermatitis participants) and outpatient period (105 days for healthy participants, 110 days for asthmatic and atopic dermatitis participants). The total duration of participation for each participant will be approximately 21 weeks for healthy participants, 25 weeks for asthmatic participants, and atopic dermatitis participants. All eligible participants will be randomly assigned to receive active agent or placebo. The study will be conducted in 2 parts. In Part 1, single ascending doses of CNTO 7160 or placebo will be administered to sequential cohorts of healthy participants as an IV infusion. In Part 2, ascending multiple doses of CNTO 7160 or placebo will be administered as IV infusions to sequential cohorts of participants with asthma or atopic dermatitis. Blood samples will be collected for assessment of pharmacokinetic and pharmacodynamics parameters in both part 1 and 2 parameters, along with assessment of safety and clinical effects in part 2. Participants' safety will be monitored throughout the study.
The present disclosure relates to a cosmetic agent for lightening keratin fibers, which contains two separate powder-formed preparations (A) and (B), each of which is packaged as a water-soluble film, and a method for lightening keratin fibers using the agent. The first preparation (A) comprises potassium peroxydisulphate, ammonium peroxydisulphate, a hydrated sodium silicate and magnesium carbonate. The second preparation comprises at least one of a percarbamide, a percarbonate and a perborate. The cosmetic agent of the present disclosure does not require the use of (free) hydrogen peroxide solution. This minimises irritation to the user. This also ensures that no overdosing of hydrogen peroxide occurs and that there is less waste peroxide to be disposed of.
1429356 Xylostasin TAKEDA YAKUHIN KOGYO KK 31 May 1973 [31 May 1972] 25912/73 Heading C2C An antibiotic, O-#-D-xylofuranosyl-(1-# 5) - O - [α - 2,6 - diamino - 2,6 - dideoxy - D- glucopyranosyl - (1-#4)] - 2 - deoxystreptamine (also known as xylostasin), of formula or a pharmaceutically acceptable salt thereof, is prepared by cultivating (a) Bacillus sp. Y399 (B. vitellinus), ATCC 21932, or a xylostasinproducing mutant thereof or (b) Bacillus sp. V-7 (B. circulans), ATCC 21933, or a xylostasinproducing mutant thereof, in a culture medium containing assimilable carbon sources, digestible nitrogen sources and other nutrients until the antibiotic is accumulated. The antibiotic may be recovered from the clarified broth by adsorption on a cation exchange resin and elution with aqueous ammonia, followed by adsorption on on activated carbon, elution with dilute hydrochloric acid and neutralization with an anionic exchange resin to produce a crude powder. The latter is dissolved in water and further purified by adsorption on cation exchange resin and eluted with aqueous ammonia. The filtrate, after concentration, is treated with acetone, the precipitate recovered, dissolved in water and further adsorbed and eluted. The fractions were pooled and concentrated to dryness to yield white xylostasin powder. Xylostasin is basic and forms salts with acids, for example, sulphuric and hydrochloric acids. Pharmaceutical compositions having antibiotic activity against bacteria comprise xylo stasin or its pharmaceutically acceptable acid salts together with a suitable excipient.
The accuracy of neuropsychological assessments relies on participants exhibiting their true abilities during administration. The Test of Memory Malingering (TOMM) is a popular performance validity test used to determine whether an individual is providing honest answers. While the TOMM has proven to be highly sensitive to those who are deliberately exaggerating their symptoms, there is a limited explanation regarding the significance of using 45 as a cutoff score. The present study aims to further investigate this question by examining TOMM scores obtained in a large sample of active-duty military personnel (N = 859, M = 26 years, SD = 6.14, 97.31% males, 72.44% white). Results indicated that no notable discrepancies existed between the frequency of participants who scored a 45 and those who scored slightly below a 45 on the TOMM. The sensitivity and specificity of the TOMM were derived using the forced-choice recognition (FCR) scores obtained by participants on the California Verbal Learning Test, Second Edition (CVLT-II). The sensitivity for each trial of the TOMM was 0.84, 0.55, and 0.63, respectively; the specificity for each trial of the TOMM was 0.69, 0.93, and 0.92, respectively. Because sensitivity and specificity rates are both of importance in this study, balanced accuracy scores were also reported. Results suggested that various alternative cutoff scores produced a more accurate classification compared to the traditional cutoff of 45. Further analyses using Fisher's exact test also indicated that there were no significant performance differences on the FCR of the CVLT-II between individuals who received a 44 and individuals who received a 45 on the TOMM. The current study provides evidence on why the traditional cutoff may not be the most effective score. Future research should consider employing alternative methods which do not rely on a single score.
ETHNOPHARMACOLOGY RELEVANCE: Sanghuangporus vaninii (S. vaninii), as a traditional large medicinal fungus, has a history of more than 2000 years in Chinese history and has been widely used to treat female diseases such as vaginal discharge, amenorrhea, and uterine bleeding, and recent pharmacological studies have also found that it has antioxidant, anti-inflammatory, and anti-tumor physiological activity, which has received more and more attention.
AIM OF THE STUDY: The objective was to evaluate cytotoxicity and the acute, subacute toxicity, and in vitro antioxidant activity of S. vaninii crude polysaccharide (SVP).
MATERIALS AND METHODS: The monosaccharide composition of SVP was determined by HPLC (high-performance liquid chromatography). The cytotoxicity of different concentrations of SVP on three types of cells (HT-22, Kupffer macrophages, HEK293) was assessed using CCk-8. The acute toxicity in vivo was evaluated for 14 days after the administration of SVP (2500,5000, or 10,000 mg/mL). For the evaluation of subacute toxicity, mice were daily treated for 28 days with SVP (2500,5000, or 10,000 mg/mL). In addition, DPPH, hydroxyl radical, and superoxide anion radical were used to evaluate the in vitro antioxidant activity of SVP.
RESULTS: SVP was not toxic in all three cell lines tested. In vitro antioxidant tests on the extracts showed that SVP possessed a strong antioxidant capacity in vitro. In the acute study, the no-observed-adverse-effect level (NOAEL) in male and female rats was 10,000 mg/kg body weight. There were also no deaths or severe toxicity associated with SVP in subacute studies. However, SVP treatment had a decreasing effect on body weight in mice of both sexes (2500, 5000, and 10000 mg/kg). At doses (5000 and 10,000 mg/kg), SVP had a reduced effect on food intake in both male and female mice. In addition, there were significant effects on organ coefficients of the liver, lung, and kidney. Hematological analysis showed significantly lower LYM (%) values in mice of both sexes, with significantly lower MCH (pg) values obtained in males (5000 mg/kg and 10000 mg/kg) and higher GRAN (%) values in females. In addition, the RDW-SD (fL) values were significantly lower in the male mice given the highest dose. Biochemical tests showed that there were no significant changes in ALT, AST, TP, and Cr levels after SVP treatment. In histopathological analysis, mild liver toxicity was observed in both female mice treated with 10,000 mg/kg SVP.
CONCLUSION: The extract of SVP showed a predominance of polysaccharide compounds, with non-toxic action in vivo. Our approach revealed SVP on the chemical composition and suggests a high margin of safety in the popular use of medicinal fungi. In conclusion, our results suggest that SVP is safe, and can be used as health care products and food.